Additionally, he helped lead Agios’ transition from an early-stage research company to a late-stage clinical organization with lead assets enasidenib and ivosidenib (now marketed as IDHIFA ® and ...
he helped lead Agios’ transition from an early-stage research company to a late-stage clinical organization with lead assets enasidenib and ivosidenib (now marketed as IDHIFA® and TIBSOVO ...
Additionally, he helped lead Agios' transition from an early-stage research company to a late-stage clinical organization with lead assets enasidenib and ivosidenib (now marketed as IDHIFA ® and ...
It’s a major change of direction for Boston-based Agios, which has been concentrating on the oncology market since its inception in 2008, bringing the Bristol Myers Squibb-partnered Tibsovo ...
It was acquired by Servier alongside IDH inhibitor stablemate Tibsovo (ivosidenib), which is already approved to treat acute myeloid leukaemia. According to Servier, the results of the INDIGO ...
In the same batch of announcements Ivosidenib (Tibsovo) was also accepted for treating adults with advanced cholangiocarcinoma, a cancer of the bile ducts. Teclistamab (Tecvayli) was accepted as well, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback